Sustainalytics’ Top Rated Sustainalytics’

Sustainalytics, Shanghai, 14 March 2022 / PRNEWswire / — WuXi Biologics (WuXi Biologics, 2260.HK) has been selected as the “highest rated company in the ESG industry for 2022″ in the latest Sustainalytics REPORT.This is the second year in a row that The company has won the award for its outstanding performance in environmental protection, social responsibility and corporate governance.Sustainalytics is a global provider of environmental, social and corporate governance (ESG) research, ratings and data to support the development and implementation of investment strategies by investors worldwide.Sustainalytics has developed ESG risk ratings and corresponding risk assessment systems for different sectors to comprehensively measure and analyze the risks that may be faced by enterprises in each sector and their risk management capabilities.The ESG ratings cover more than 14,000 companies in 42 industries worldwide.According to the ESG ratings released by Sustainalytics in February 2022, Pharmacopoeia is rated low risk and ranked in the top 4% of the industry.”We are honored to have received this recognition from Sustainalytics,” said Dr. Zhisheng Chen, CEO of Yaomingbio and chairman of the ESG Committee.Sustainable development is the strategic focus of the business development of Pharming and is also the key driving force for the company to achieve high-quality and long-term development.As a global biopharmaceutical CRDMO service company, we are committed to enabling our global partners to accelerate the development and production of biopharmaceutical products for the benefit of patients worldwide.”Yao Ming bio has always implemented its sustainable development strategy and regards ESG as the core of corporate governance and strategic cornerstone of global business development.At the beginning of 2021, the Board of Directors of Yaoming Biotechnology set up ESG Committee and established a special working group, aiming to root the concept of sustainable development in the company’s long-term development strategy and daily operation and management, and promote the implementation and implementation of the company’s sustainable development strategy.According to the recent third-party ESG survey data, The core competitiveness of Pharaox in aspects of compliance management, risk control, product quality, social and environmental responsibility has been highly recognized by multiple stakeholders.About Pharmbio Pharmbio (stock code: 2269.HK) is a global contract research, development and manufacturing services (CRDMO) company.Through an open and integrated biopharmaceutical capability and technology enabling platform, the company provides a full range of end-to-end services to help partners discover, develop and produce biopharmaceutical products from concept to commercial production, accelerating the global biopharmaceutical research and development process, reducing research and development costs and benefiting patients.Yao Ming has more than 10,000 employees in China, the United States, Ireland, Germany and Singapore.With the professional service team of these employees, together with superior technology and insights, the company provides customers with cost-effective biologic solutions.By the end of 2021, The company has helped its customers develop and manufacture a total of 480 projects, including nine commercial production projects.The company regards environment, society and governance (ESG) as an important part of its business development and enterprise spirit, and is committed to becoming a global ESG leader in the field of bio-pharmaceutical CRDMO, such as the application of greener next-generation biopharmaceutical technologies and energy to lead the industry development.The company has established an ESG Committee, led by the CEO, to fully implement the ESG strategy and implement the commitment to sustainable development.For more information, please visit:.

Leave a Reply

Your email address will not be published.